Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-508 interaction with Midazolam and Rosuvastatin
NCT06979973Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2025
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, open-label trial of CKD-508 in hypercholesterolemia, sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration of midazolam at 24 hours, Area Under the Concentration-Time Curve to the Last Measurable Concentration of midazolam at 24 hours and 7 more. Started May 2025; status: completed.
02
Drugs
CKD-508
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06979973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979973.